-
公开(公告)号：US20050053586A1
公开(公告)日：2005-03-10
申请号：US10655275
申请日：2003-09-04
Applicant: Bryan Conn , Barry Smith , Albert Rubin , Kurt Stenzel
Inventor： Bryan Conn , Barry Smith , Albert Rubin , Kurt Stenzel
IPC: C12N5/074 , A01N1/02 , A61K35/13 , A61K35/14 , A61K35/48 , A61K35/545 , A61K48/00 , C12N5/00 , C12N5/071 , C12N5/0789 , C12N5/08
CPC classification number: C12N5/0693 , A01N1/0205 , A01N1/0231 , A61K35/13 , A61K35/545 , C12N5/0012 , C12N5/0606 , C12N2502/02 , C12N2533/76
Abstract: The invention relates to the stem cells, embryonic stem cells in particular. It has been found that, when these stem cells are entrapped such that their proliferation is inhibited, they produce material which inhibits the proliferation of other, non-entrapped cells, including stem cells and neoplastic and/or hyperproliferative, but otherwise normal cells. It has also been found that entrapped cancer cells will produce material which inhibits the proliferation of stem cells. Further, it has been found that the entrapment of the stem cells inhibits their differentiation and thus the entrapment process can serve as a long-term storage device for maintaining the undifferentiated state of at least a portion of the entrapped cells.
Abstract translation: 本发明特别涉及干细胞，胚胎干细胞。 已经发现，当这些干细胞被捕获使得其增殖被抑制时，它们产生抑制其它非包埋细胞（包括干细胞，肿瘤和/或过度增殖，但是其他正常细胞）增殖的材料。 也已经发现，截留的癌细胞将产生抑制干细胞增殖的物质。 此外，已经发现，干细胞的捕获抑制其分化，因此捕获过程可以用作长期存储装置，用于保持至少一部分包埋细胞的未分化状态。
-
公开(公告)号：US5660858A
公开(公告)日：1997-08-26
申请号：US627187
申请日：1996-04-03
Applicant: Indu Parikh , Awadhesh Mishra
Inventor： Indu Parikh , Awadhesh Mishra
CPC classification number: A61K9/1075 , A61K38/13 , Y10S514/938 , Y10S514/943
Abstract: This invention comprises pharmaceutical compositions consisting essentially of an oil-in-water emulsion containing a synthetic medium chain triglyceride in which is dissolved a therapeutically effective amount of a cyclosporin, phospholipid and optionally free fatty acid or a salt thereof, non-ionic surfactant, ionic surfactant, glycerol, salts, buffers, preservative, osmotic modifier and antioxidant.
Abstract translation: 本发明包括主要由含有合成中链甘油三酯的水包油乳液组成的药物组合物，其中溶解有治疗有效量的环孢菌素，磷脂和任选的游离脂肪酸或其盐，非离子表面活性剂，离子 表面活性剂，甘油，盐，缓冲液，防腐剂，渗透调节剂和抗氧化剂。
-
公开(公告)号：US5326690A
公开(公告)日：1994-07-05
申请号：US130239
申请日：1993-10-01
Applicant: Yan Xu , Anne E. Goodbody
Inventor： Yan Xu , Anne E. Goodbody
CPC classification number: A61K35/13
Abstract: Herein described is an ovarian cancer activating factor that has been isolated from ovarian cancer ascites fluid. The factor may be utilized in its isolated form in a screening program aimed at identifying inhibitors of factor-mediated ovarian cancer activation, or as a growth supplement useful for culturing ovarian and other cancer cell lines.
-
公开(公告)号：US5277917A
公开(公告)日：1994-01-11
申请号：US41974
申请日：1993-04-02
Applicant: Yan Xu , Anne E. Goodbody
Inventor： Yan Xu , Anne E. Goodbody
CPC classification number: A61K35/13
Abstract: Herein described is an ovarian cancer activating factor that has been isolated from ovarian cancer ascites fluid. The factor may be utilized in its isolated form in a screening program aimed at identifying inhibitors of factor-mediated ovarian cancer activation, or as a growth supplement useful for culturing ovarian and other cancer cell lines.
Abstract translation: 本文描述了已经从卵巢癌腹水中分离的卵巢癌激活因子。 该因子可以以其分离形式用于旨在鉴定因子介导的卵巢癌激活的抑制剂的筛选程序中，或作为用于培养卵巢癌和其它癌细胞系的生长补体。
-
45.发明申请
公开(公告)号：US20240417696A1
公开(公告)日：2024-12-19
申请号：US17927335
申请日：2021-05-17
Applicant: MDimune Inc.
Inventor： Shin Gyu Bae , Seung Wook Oh , Dong Woo Han , Jun Sik Yoon , Ji Hye Lee
IPC: C12N5/09 , A61K9/16 , A61K9/20 , A61K9/48 , A61K35/13 , A61K35/17 , A61K35/28 , C12N5/0775 , C12N5/0783
Abstract: The present disclosure relates to a cell-derived vesicle rich in intracellular protein homeostasis regulators, and to a method of preparing same. The cell-derived vesicle of the present disclosure is characterized by containing an abundance of a specific protein compared to that in a naturally secreted exosome or the originated cell, and by virtue of said characteristic, can be utilized for various purposes such as in a pharmaceutical composition, a diagnostic composition, and a composition for drug delivery. Using the cell-derived vesicle rich in intracellular protein homeostasis regulators and the method of preparing same of the present disclosure, it is possible to easily deliver the intracellular protein homeostasis regulators to a target, such as a cell, thereby easily maintaining protein homeostasis in cells. Accordingly, the present disclosure may also be utilized for “a use for the prevention or treatment of disease caused by a protein homeostasis regulation failure within cells” or “a use for preventing aging”, and thus can be widely used in the drug industry.
-
公开(公告)号：US20240398861A1
公开(公告)日：2024-12-05
申请号：US18689800
申请日：2022-09-06
Inventor： Kevin A. Cassady , Uksha Saini , Dawn Chandler , Ruoning Wang , Nicolas Wein
Abstract: This disclosure relates to populations and compositions of purified cancer cell-derived vesicles and uses thereof.
-
47.发明授权
公开(公告)号：US12159700B2
公开(公告)日：2024-12-03
申请号：US17238092
申请日：2021-04-22
Applicant: Iovance Biotherapeutics, Inc.
Inventor： Anne Brooks , Steve Macrides , Kristin Lanzi
IPC: G16H20/00 , A61K35/13 , A61K39/00 , C12N5/0783 , C12N5/09 , G06Q10/0832 , G16H10/60 , G16H80/00
Abstract: A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.
-
公开(公告)号：US11926647B2
公开(公告)日：2024-03-12
申请号：US17226028
申请日：2021-04-08
Applicant: Pastoral Greenhouse Gas Research Limited
Inventor： Eric Heinz Altermann , Graeme Trevor Attwood , Dong Li , William John Kelly , Zhanhao Kong , Sinead Christine Leahy
IPC: C07K14/005 , C12N1/20 , C12N7/00 , C12N9/64 , A61K35/13
CPC classification number: C07K14/005 , C12N1/20 , C12N7/00 , C12N9/641 , A61K35/13 , C07K2319/00 , C12N2795/10021 , C12N2795/10022
Abstract: The invention encompasses components from microbial cells which are useful for antibody production, including peptides, polypeptides comprising these peptides, polynucleotides which encode these peptides or polypeptides, and antibodies directed to these peptides, polypeptides, or polynucleotides. The invention also encompasses to expression vectors and host cells for producing these peptides, polypeptides, polynucleotides, and antibodies. The invention further encompasses methods and compositions, especially vaccine compositions, for detecting, targeting, and inhibiting microbial cells, especially methanogen cells, using one or more of the disclosed peptides, polypeptides, polynucleotides, antibodies, expression vectors, and host cells.
-
公开(公告)号：US20230338539A1
公开(公告)日：2023-10-26
申请号：US18010483
申请日：2021-06-07
Applicant: Immunolight, LLC
Inventor： Frederic A. BOURKE, Jr. , Harold WALDER , Zakaryae FATHI
CPC classification number: A61K41/0066 , A61K35/13 , A61K31/37 , A61P35/00 , A61K39/0011 , A61N5/1048 , A61K2039/585 , A61N2005/1098 , A61N2005/1089
Abstract: A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.
-
公开(公告)号：US11707518B2
公开(公告)日：2023-07-25
申请号：US17699055
申请日：2022-03-18
Applicant: Gholam A. Peyman
Inventor： Gholam A. Peyman
IPC: A61K39/215 , A61K31/155 , A61K31/422 , A61K31/506 , A61K39/39 , A61K39/395 , A61K31/519 , A61K31/5377 , A61K45/06 , A61K35/13 , A61K35/66 , A61K35/74 , A61K35/76 , A61K36/06 , A61K39/00 , C12N1/00 , C12N1/02
CPC classification number: A61K39/215 , A61K31/155 , A61K31/422 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K35/13 , A61K35/66 , A61K35/74 , A61K35/76 , A61K36/06 , A61K39/00 , A61K39/39 , A61K39/3955 , A61K45/06 , C12N1/00 , C12N1/02 , A61K2039/543 , A61K2039/55511 , C12N2501/999
Abstract: A therapeutic vaccination method includes growing and harvesting viruses, bacteria, fungi, parasites, or tumor cells on a cell culture or other appropriate medium; killing the viruses, bacteria, fungi, parasites, or tumor cells in the cell culture or other appropriate medium with a dose of methylene blue; separating the dead viruses, bacteria, fungi, parasites, or tumor cells from a remainder of the cell culture or other appropriate medium using a filter and/or centrifuge; adding antivirals, antibacterials, antifungals, antiparasitics, and/or anti-neoplastic medications at non-toxic therapeutic concentrations to the dead viruses, bacteria, fungi, parasites, or tumor cells so as to form a therapeutic vaccine; and administering the therapeutic vaccine to a patient in need thereof to simultaneously produces a therapeutic response and a humoral and cellular immune response in the body of the patient without resulting in deleterious side effects to the patient.
